Kupando, a Germany-based biotech company developing therapies for cancer and infectious diseases, has raised an additional €10 million in Series A funding, bringing the total to approximately $23 million. The financing was co-led by Remiges Ventures and LifeCare Partners, with participation from Brandenburg Kapital, High-Tech Gründerfonds, Ventura BioMed Investors, and CARMA Fund.
The company plans to use the proceeds to advance the Phase 1b clinical study of its lead candidate, KUP101, in patients with advanced solid tumors, while also accelerating its preclinical pipeline targeting infectious diseases.
Kupando is focused on leveraging innate immune stimulation and trained immunity through dual Toll-Like Receptor agonists. Its lead asset, KUP101, is a dual TLR4 and TLR7 agonist designed to activate the immune system to fight cancer and infections. The therapy has demonstrated a strong preclinical profile and is being positioned for further clinical development.
The company’s broader pipeline includes programs targeting oncology indications such as skin cancer and solid tumors, as well as infectious disease applications including antimicrobial resistance and vaccine-related programs.
Kupando is led by CEO and Founder Johanna Holldack, who brings decades of experience in drug development across oncology and vaccines. The company aims to address critical unmet medical needs, particularly in treatment-resistant cancers and antimicrobial-resistant infections, by developing first-in-class immunotherapies.
